Please use this identifier to cite or link to this item:
Title: A guide to preparation of patients with inflammatory bowel diseases for anti-TNF-alpha therapy
Authors: Fonseca Chebli, Julio Maria
Gaburri, Pedro Duarte
Chebli, Liliana Andrade
Rocha Ribeiro, Tarsila Campanha da
Tavares Pinto, Andre Luiz
Ambrogini Junior, Orlando [UNIFESP]
Mourao Cintra Damiao, Aderson Omar
Univ Fed Juiz de Fora
Universidade Federal de São Paulo (UNIFESP)
Universidade de São Paulo (USP)
Keywords: Inflammatory Bowel Disease
Ulcerative Colitis
Agents, Biological
Issue Date: 26-Mar-2014
Publisher: Int Scientific Literature, Inc
Citation: Medical Science Monitor. Smithtown: Int Scientific Literature, Inc, v. 20, p. 487-498, 2014.
Abstract: Current therapy of moderate-to-severe inflammatory bowel disease (IBD) often involves the use of anti-tumor necrosis factor alpha (TNF-alpha) agents. Although very effective, theses biologics place the patient at increased risk for developing infections and lymphomas, the latter especially when in combination with thiopurines. Appropriate patient selection, counseling, and education are all important features for the successful use of anti-TNF-alpha therapy. A thorough history to rule-out contraindications of this therapy and emphasis on monitoring guidelines are important steps preceding administration of anti-TNF-alpha agents. This therapy should only be considered if a recent evaluation has established that the patient has active IBD. In addition, it is important to exclude disease mimickers. Anti-TNF-alpha agents have been considered to present a globally favorable benefit/risk ratio. However, it is important that in routine practice, initiation of anti-TNF-alpha therapy be carefully discussed with the patient, extensively explaining the potential benefits and risks of such treatment. Prior to starting anti-TNF-alpha therapy, the patients need to be screened for latent tuberculosis, hepatitis B virus infection, and (usually) hepatitis C virus and HIV infection. Vaccination schedules of IBD patients should be evaluated and updated prior to the commencement of anti-TNF-alpha therapy. Ordinarily, immunization in adult patients with IBD should not deviate from recommended guidelines for the general population. With the exception of live vaccines, immunizations can be safely administered in patients with IBD, even those on immunosuppressants or biologics. The purpose of this review is providing an overview of appropriate steps to prepare patients with IBD for anti-TNF-alpha therapy.
ISSN: 1643-3750
Other Identifiers:
Appears in Collections:Resenha

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.